Yoga Nidra in Resistant Hypertensio

Phase 1

• Conditions: Health Condition 1: I10- Essential (primary) hypertension

• Registration Number: CTRI/2020/02/023365
• Lead Sponsor: A

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Last Update Posted: 24 November 2021

Recruitment & Eligibility

• Status: ot Yet Recruiting
• Sex: Not specified
• Target Recruitment: 0

Inclusion Criteria

1. Patients diagnosed with resistant hypertension as per the diagnostic criteria devised by American Heart Association (AHA) [i.e. patients who fail to achieve target blood pressure of <130/80 mmHg despite treatment with >=3 antihypertensive medications]

2. Willingness to participate in the study by signing written informed consent

Exclusion Criteria

1. Patient with the history of Pseudo-Resistant Hypertension (non-adherence to medication, high salt intake, white coat hypertension, improper BP measurement), and Resistant Hypertension due to secondary causes like common substance (antidepressants such as venlafaxine, phenylephrine, glucocorticoids, erythropoietin, calcineurin inhibitors, hormonal contraceptives, cocaine, amphetamine, ecstasy) Obstructive Sleep Apnoea, Obesity, Hyperaldosteronism, Pheochromocytoma

2. Patients who are currently enrolled in any other research study

3. Patients with other cardiovascular conditions like untreated coronary artery disease, heart failure, rheumatic heart disease and congenital heart disease

4. Patients with Chronic Kidney Disease (GFR >/ <90, albumin:creatinine ratio >=3 with presence of markers of kidney damage)

5. Patients with hepatic, pulmonary, endocrinal, neurological, psychiatric disorders and/or complications

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Assessment of systolic blood pressure level using 24-hours Ambulatory Blood Pressure Monitoring (ABPM)Timepoint: Baseline and at 6 month

Secondary Outcome Measures

Name	Time	Method
Assessment of autonomic changes by measuring Heart Rate Variability (HRV) using Holter monitorTimepoint: Baseline and at 6 month;Assessment of Depression, Anxiety and Stress level using DASS-21 QuestionnaireTimepoint: Baseline and at 6 month;Assessment of Quality of Life using SF-36 QuestionnaireTimepoint: Baseline and at 6 month